Amorfix, Aragen Bioscience collaborate to develop high-affinity monoclonal antibodies against targets for cancer
Amorfix Life Sciences and Aragen Bioscience, Inc. announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Using its proprietary ProMIS(TM) computational platform discovery technology, Amorfix has identified several disease specific epitopes (“DSEs”) on misfolded Fas receptor. Aragen will use those DSEs to …

Read more on News-Medical-Net